Physician profile
Eric W Jahnke
NPI 1134195977
$4,027.24
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $260 · 2021: $1,210 · 2022: $1,861 · 2023: $167 · 2024: $89.61.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $256.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,302.14 | 2019-2022 | |
| Janssen Biotech, INC. | $473.87 | 2020-2024 | Stelara, Simponi Aria, Simponi |
| Gilead Sciences, INC. | $266.66 | 2019-2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $154.57 | 2019-2021 | |
| Nestle Healthcare Nutrition INC. | $141.10 | 2020-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $138.58 | 2019-2022 | |
| Genzyme Corporation | $131.73 | 2022 | |
| Ferring Pharmaceuticals INC. | $94.71 | 2019-2022 | |
| Celgene Corporation | $85.08 | 2021-2022 | |
| Pfizer INC. | $77.02 | 2019 | |
| Shionogi INC | $50.96 | 2019 | |
| Allergan, INC. | $24.62 | 2019 | |
| Phathom Pharmaceuticals, INC. | $19.68 | 2024 | Voquezna |
| Braintree Laboratories, INC. | $15.97 | 2021 | |
| Intercept Pharmaceuticals, INC. | $13.71 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $13.27 | 2021 | |
| Redhill Biopharma INC. | $12.24 | 2022 | |
| Dova Pharmaceuticals | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Jahnke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.